Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT00653744 Completed - Clinical trials for Hypercholesterolemia

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)

ARIES
Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in African American subjects with hypercholesterolemia.

NCT ID: NCT00651963 Completed - Clinical trials for Lipid Metabolism Disorder

Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)

Start date: September 2004
Phase: Phase 4
Study type: Interventional

Gather additional efficacy and safety (pharmacovigilance) information in the usual daily care in patients with Dyslipidemia on ezetimibe under real conditions in Colombia associated with statins.

NCT ID: NCT00647543 Completed - Dyslipidemias Clinical Trials

Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand

Start date: August 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy of atorvastatin in lowering cholesterol on patients from Thailand with high cholesterol.

NCT ID: NCT00645775 Completed - Obesity Clinical Trials

Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome

Start date: November 2006
Phase: N/A
Study type: Interventional

The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.

NCT ID: NCT00645151 Completed - Dyslipidemias Clinical Trials

A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol

LA ATGOAL
Start date: April 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.

NCT ID: NCT00644709 Completed - Dyslipidemias Clinical Trials

A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)

Start date: September 2003
Phase: Phase 4
Study type: Interventional

A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of <115 mg/dL

NCT ID: NCT00644670 Completed - Dyslipidemias Clinical Trials

A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol

Start date: June 2003
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the effectiveness of atorvastatin in lowering cholesterol and getting these high risk patients to their goals of LDL <115 mg/dl across starting doses of 10 mg, 20 mg, or 40 mg with one step titration.

NCT ID: NCT00639158 Completed - Clinical trials for Coronary Heart Disease

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.

NCT ID: NCT00634673 Completed - Clinical trials for Type 2 Diabetes Mellitus

Postprandial Fatty Acids and FABP2 in Type 2 Diabetes Mellitus (DM)

Start date: June 2006
Phase: N/A
Study type: Interventional

This study will be conducted in type 2 diabetic patient's to evaluate the if there is a different response of serum lipids after a standard meal (rich in saturated fatty acids) in patients who have the presence of a genetic alteration. This alteration that will be evaluated is a polymorphism, change of an amino acid in the gene of FABP2. This gene that can influence the absorption of lipids in the intestine and subjects who have the altered genotype (presence of T allele) can have an abnormal lipid profile as compared to subjects without this genotype.

NCT ID: NCT00630877 Completed - Dyslipidemia Clinical Trials

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin (ASA) daily for 6 weeks. The FAST is a questionnaire that was developed to provide a detailed assessment of flushing symptoms and their impact in patients receiving niacin therapy. The effect of aspirin on flushing symptoms, as measured by the FAST, was also evaluated.